Due to the FDA's recent decision to end enforcement discretion and the reduced availability through OpenBiome, we currently do not have access to FMT for patients.

For patients suffering from recurrent Clostridioides difficile infection, we recommend considering one of the available preventative microbiota-based therapies: Rebyota (fecal microbiota, live-jslm, enema) or Vowst (fecal microbiota spores, live-brpk, capsules). Please note that these products are approved for prevention—not treatment—of recurrent C. difficile infection, and should be administered following the completion of an appropriate antibiotic regimen, in accordance with prescribing instructions.

Additional information, including insurance coverage resources and patient assistance programs, can be found on the respective manufacturers' websites and coverage forms.